Welcome to our dedicated page for Rapport Therapeutics news (Ticker: RAPP), a resource for investors and traders seeking the latest updates and insights on Rapport Therapeutics stock.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company that regularly issues news about its precision neuroscience programs for neurological and psychiatric disorders. The company’s updates often center on RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being evaluated in drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain.
News for RAPP commonly includes clinical trial milestones, such as Phase 2a results in focal onset seizures, post hoc analyses presented at scientific meetings, and plans for registrational Phase 3 programs. Rapport has reported statistically significant reductions in long episodes and clinical seizures in its Phase 2a FOS trial, along with additional analyses on early onset of action, consistency of response, and improvements in seizure severity measures.
Investors and clinicians following Rapport can also expect announcements about regulatory interactions with the U.S. Food and Drug Administration, including end-of-Phase 2 meetings, clinical hold updates, and investigational new drug (IND)-enabling activities. The company provides updates on its long-acting injectable formulation of RAP-219, its α6β4 nicotinic acetylcholine receptor program for chronic pain and migraine, and other discovery and preclinical efforts in hearing and vestibular disorders.
RAPP news flow further covers financial and corporate developments, such as public offerings of common stock under an effective shelf registration statement, quarterly financial results, and participation in healthcare and investor conferences. For readers tracking Rapport Therapeutics, this news stream offers insight into the progress of its RAP technology platform, the evolution of its epilepsy portfolio, and the status of its broader pipeline in neurology and psychiatry.
Rapport Therapeutics (NASDAQ: RAPP) reported Q3 2024 financial results and business updates. The company's lead program RAP-219 continues Phase 2a trials for focal epilepsy, with topline data expected mid-2025. The FDA placed a clinical hold on their Investigational New Drug Application for diabetic peripheral neuropathic pain. Four new biotech leaders joined the Board of Directors. Q3 financial results showed a net loss of $17.5 million, with R&D expenses of $15.5 million and G&A expenses of $6.1 million. The company ended Q3 with $320.7 million in cash and equivalents, expected to fund operations through 2026.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule precision medicines for CNS disorders, has announced its participation in two major healthcare conferences in November 2024. The company will engage in fireside chats at the Stifel Healthcare Conference in New York City on November 18 at 1:15pm ET, and the Jefferies London Healthcare Conference on November 20 at 4:00pm GMT/11am ET. Live and archived webcasts will be available on the company's investor relations website.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focusing on CNS disorders, announced presentations at two upcoming epilepsy conferences. At the 15th Annual European Epilepsy Congress in Rome (Sept. 7-11, 2024), they will present on the novel design of a Phase 2a proof-of-concept trial for RAP-219 in drug-resistant focal epilepsy. At the 2024 Epilepsy Foundation Pipeline Conference in Atlanta (Sept. 25-26, 2024), they will discuss RAP-219's mechanism of action and the trial design.
Presentations include:
- EEC: 'Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219' (Sept. 08, 2024)
- Pipeline Conference: 'RAP-219 a novel, potent, and selective negative modulator of AMPAR TARPγ8' (Sept. 26, 2024)
Presentations will be available on Rapport's website after the conferences.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule medicines for CNS disorders, has announced its participation in two upcoming investor conferences. The company will present at:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 5, 2024, at 4:50 pm ET.
2. TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on September 26, 2024, at 11:40 am ET.
A live and archived webcast of the Morgan Stanley Conference fireside chat will be available on the company's investor relations website. This presentation offers investors an opportunity to gain insights into Rapport Therapeutics' progress in developing innovative treatments for central nervous system disorders.
Contineum Therapeutics (Nasdaq: CTNM) reported Q2 2024 financial results and recent business highlights. Key points include:
- Strong cash position of $219 million at Q2 end
- Appointed Troy Ignelzi and Sarah Boyce to Board of Directors
- Strengthened management team with John Healy and Kristina Haeckl
- Enrollment on track for PIPE-307 Phase 2 VISTA trial in RRMS
- Published preclinical and clinical results on PIPE-307 and PIPE-791
- Completed IPO with net proceeds of $107.9 million
Financial results:
- R&D expenses: $7.9 million (Q2 2024) vs $9.5 million (Q2 2023)
- G&A expenses: $3.0 million (Q2 2024) vs $1.6 million (Q2 2023)
Rapport Therapeutics (RAPP) reported Q2 2024 financials and provided a business update. Key highlights include:
1. Completed IPO, raising $174.4 million in gross proceeds
2. Phase 2a trial of RAP-219 in focal epilepsy on track for Q3 2024 initiation, with topline data expected mid-2025
3. Two additional proof-of-concept trials for RAP-219 planned: peripheral neuropathic pain (2H 2024) and bipolar disorder (2025)
4. Q2 2024 net loss: $18.1 million
5. Cash position: $336.1 million, expected to fund operations through end of 2026
6. Advancing preclinical programs, including RAP-199 and two nAChR discovery-stage programs
Rapport Therapeutics (Nasdaq: RAPP) will present preclinical data on RTX-1738, an analog to their lead product candidate RAP-219, at the IASP 2024 World Congress on Pain in Amsterdam. The poster presentation, scheduled for August 6, 2024, will showcase RTX-1738's analgesic activity across various acute and chronic pain models.
RTX-1738 is an AMPAR negative allosteric modulator designed to target TARPγ8, a receptor associated protein. This approach aims to achieve neuroanatomical specificity in treating central nervous system disorders. The company's lead candidate, RAP-219, is currently in a Phase 2a trial for drug-resistant focal epilepsy. Rapport plans to initiate additional Phase 2a trials for RAP-219 in peripheral neuropathic pain and bipolar disorder in late 2024 and 2025, respectively.
Rapport Therapeutics, a clinical-stage biotechnology firm specializing in central nervous system disorder treatments, closed its initial public offering (IPO) on June 12, 2024. The IPO involved 9,200,000 shares of common stock at $17.00 per share, totaling approximately $174 million, including the full exercise of the underwriters' option to purchase additional shares and a concurrent private placement. Trading began on June 7, 2024, under the ticker symbol 'RAPP'. Goldman Sachs, Jefferies, TD Cowen, and Stifel managed the offering. The concurrent private placement involved selling 1,058,824 shares to existing stockholders. The proceeds will be used to further Rapport's development of small molecule medicines.
Rapport Therapeutics, a clinical-stage biotech company, announced the pricing of its IPO at $17.00 per share for 8 million shares. Trading on the Nasdaq under the symbol 'RAPP' begins June 7, 2024, with the offering expected to close on June 10, 2024. Additionally, the company offers a 30-day option for underwriters to purchase up to 1.2 million more shares. Concurrently, Rapport will sell 1,058,824 shares in a private placement at the IPO price. Combined, these transactions aim to raise approximately $154 million before expenses, contingent on customary closing conditions. Joint book-running managers include Goldman Sachs, Jefferies, TD Cowen, and Stifel.